Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Five Late-Stage Products In Lilly’s Pipeline Could Launch By End Of Decade

This article was originally published in The Pink Sheet Daily

Executive Summary

Mid- and late-stage pipeline opportunities, including gamma secretase inhibitor for Alzheimer’s and long-acting versions of Byetta and Zyprexa, fuel Lilly’s optimism.

You may also be interested in...



Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses

Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18

Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses

Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18

Lilly Cuts Arzoxifene Losses, Will Not File NDA

After initial results from a five-year, Phase III trial showed the drug fell short on key secondary outcome measures, Lilly has decided not to file the application with FDA.

Related Content

Topics

UsernamePublicRestriction

Register

PS066653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel